Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications

Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases

Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke

Hopstem Biotechnology at 2024 CASSS CGPT Symposium

Hopstem Biotechnology to Participate in the 2024 BIO International Convention in San Diego

Hopstem to Showcase hNPC01 Clinical Data at 2024 ASGCT Annual Meeting in Baltimore